ID   SCCT2
AC   CVCL_G308
SY   SCC T2; T2
DR   cancercelllines; CVCL_G308
DR   CancerTools; 153672
DR   Cosmic; 1608869
DR   Cosmic; 2688676
DR   GEO; GSM2611488
DR   GEO; GSM2611489
DR   GEO; GSM2611490
DR   Wikidata; Q54952397
DR   Ximbio; 153672
RX   PubMed=21602893;
RX   PubMed=22006338;
RX   PubMed=24662767;
RX   PubMed=30202019;
RX   PubMed=31336867;
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asn71Ile (c.212A>T); Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Cys409Phe (c.1226G>T); Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Glu415Asp (c.1245G>T); Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Asp469Gly (c.1406A>G); Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; c.1108+1G>A; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Cys433Tyr (c.1298G>A); Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Gly1751Asp (c.5252G>A); ClinVar=VCV001980813; Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Arg2131Lys (c.6392G>A); Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Pro2343Ser (c.7027C>T); Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.375+1G>T; ClinVar=VCV000635393; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=21602893; PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ser (c.832C>T); ClinVar=VCV000376642; Zygosity=Unspecified (PubMed=21602893; PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Leu (c.833C>T); ClinVar=VCV000232497; Zygosity=Unspecified (PubMed=21602893; PubMed=24662767).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Hand, skin; UBERON=UBERON_0001519.
ST   Source(s): PubMed=31336867
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 11,14
ST   D16S539: 10,11
ST   D18S51: 12,13
ST   D19S433: 14,16
ST   D21S11: 28,31
ST   D2S1338: 17,20
ST   D3S1358: 15
ST   D5S818: 11,12
ST   D7S820: Not_detected
ST   D8S1179: 13,15
ST   FGA: 22
ST   TH01: 6
ST   TPOX: 8,9
ST   vWA: 15,18
DI   NCIt; C4819; Skin squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   66Y
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 30-01-24; Version: 16
//
RX   PubMed=21602893; DOI=10.1038/onc.2011.180; PMCID=PMC3219832;
RA   Watt S.A., Pourreyron C., Purdie K.J., Hogan C., Killick-Cole C.L.,
RA   Foster N., Pratt N., Bourdon J.-C., Appleyard M.V.C.L., Murray K.,
RA   Thompson A.M., Mao X., Mein C.A., Bruckner-Tuderman L.K., Evans A.,
RA   McGrath J.A., Proby C.M., Foerster J., Leigh I.M., South A.P.;
RT   "Integrative mRNA profiling comparing cultured primary cells with
RT   clinical samples reveals PLK1 and C20orf20 as therapeutic targets in
RT   cutaneous squamous cell carcinoma.";
RL   Oncogene 30:4666-4677(2011).
//
RX   PubMed=22006338; DOI=10.1073/pnas.1114669108; PMCID=PMC3203814;
RA   Wang N.J., Sanborn Z., Arnett K.L., Bayston L.J., Liao W., Proby C.M.,
RA   Leigh I.M., Collisson E.A., Gordon P.B., Jakkula L.R., Pennypacker S.,
RA   Zou Y., Sharma M., North J.P., Vemula S.S., Mauro T.M., Neuhaus I.M.,
RA   LeBoit P.E., Hur J.S., Park K., Huh N., Kwok P.-Y., Arron S.T.,
RA   Massion P.P., Bale A.E., Haussler D., Cleaver J.E., Gray J.W.,
RA   Spellman P.T., South A.P., Aster J.C., Blacklow S.C., Cho R.J.;
RT   "Loss-of-function mutations in Notch receptors in cutaneous and lung
RT   squamous cell carcinoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:17761-17766(2011).
//
RX   PubMed=24662767; DOI=10.1038/jid.2014.154; PMCID=PMC4753672;
RA   South A.P., Purdie K.J., Watt S.A., Haldenby S., den Breems N.Y.,
RA   Dimon M., Arron S.T., Kluk M.J., Aster J.C., McHugh A., Xue D.J.,
RA   Dayal J.H.S., Robinson K.S., Rizvi S.M.H., Proby C.M., Harwood C.A.,
RA   Leigh I.M.;
RT   "NOTCH1 mutations occur early during cutaneous squamous cell
RT   carcinogenesis.";
RL   J. Invest. Dermatol. 134:2630-2638(2014).
//
RX   PubMed=30202019; DOI=10.1038/s41467-018-06027-1; PMCID=PMC6131170;
RA   Inman G.J., Wang J., Nagano A., Alexandrov L.B., Purdie K.J.,
RA   Taylor R.G., Sherwood V., Thomson J., Hogan S., Spender L.C.,
RA   South A.P., Stratton M.R., Chelala C., Harwood C.A., Proby C.M.,
RA   Leigh I.M.;
RT   "The genomic landscape of cutaneous SCC reveals drivers and a novel
RT   azathioprine associated mutational signature.";
RL   Nat. Commun. 9:3667.1-3667.14(2018).
//
RX   PubMed=31336867; DOI=10.3390/ijms20143428; PMCID=PMC6678499;
RA   Hassan S., Purdie K.J., Wang J., Harwood C.A., Proby C.M.,
RA   Pourreyron C., Mladkova N., Nagano A., Dhayade S., Athineos D.,
RA   Caley M., Mannella V., Blyth K., Inman G.J., Leigh I.M.;
RT   "A Unique panel of patient-derived cutaneous squamous cell carcinoma
RT   cell lines provides a preclinical pathway for therapeutic testing.";
RL   Int. J. Mol. Sci. 20:3428.1-3428.26(2019).
//